Net worth tracking
Login Sign Up
Become a Premium Member
  • All Opinions
  • Top Picks
  • Experts
  • Companies
  • Discover
Watch List
Home » Stock Lists

Top Stocks with Groundbreaking Potential in the DNS Manipulation and Gene-Editing Markets

Melisa R. H. Posted On June 18, 2019
0
0
Shares
  • Share On Facebook
  • Tweet It

Bill Gates has known investments in the gene-editing industry.

Genetic Engineering is the field of science that manipulates DNA in order to change the gene expression. This technology is revolutionary as gene-editing and gene therapy could help people suffering from genetic disorders, as well as making humans more healthy. Applications include alleviating autoimmune disease, treatment of neurodegenerative disease, and other genetic disorders.

The field is expanding quickly, with more and more companies investing heavily into genetic engineering, especially the CRISPR/Cas9 System. CRISPR technology is considered the foremost precision gene editing tool.

Here are the top companies in the field:

👨‍⚕️ Healthcare

Agilent Technologies (A-N)
This company is a spin-off from Hewlett-Packard, which broke away in 1999. At the time, their IPO was the largest in history in Silicon Valley. They announced on June 18, 2019 the opening of a production facility in Colorado to produce nucleic acid-based therapeutics.

Agilent Technologies (A-N) — Stockchase
Agilent Technologies (A-N) — Stockchase

It's been marching up for the last 16 months, doubling since the start of Covid. A lot of this rise came from Covid testing. Yesterday, they reported a top- and bottom-line beat, as revenues grew 26% YOY, driven by their pharma, chemical and energy businesses. He loves it. Amid sector rotations in the past year,…

stockchase.com stockchase.com

Biogen IDEC Inc. (BIIB-Q)
A biotechnology company that focuses on treatments for neurodegenerative, and autoimmune diseases. They recently experienced a sell-off following news that they shut down a previously promising drug for Alzheimer’s. They acquired Nightstar Therapeutics this year, who focus on adeno-associated virus based gene-therapies.

Biogen IDEC Inc. (BIIB-Q) — Stockchase
Biogen IDEC Inc. (BIIB-Q) — Stockchase

They own almost nothing in the Health Care space and Biotech is particularly weak.

stockchase.com stockchase.com

Charles River Labs Intl (CRL-N)
A preclinical and clinical laboratory company for pharmaceutical and biotech firms. They are also a contractor that offers research and development outsourcing services. They offer a genetically engineered animal models and services, as well as CRISPR/Cas9 System research.

Charles River Labs Intl (CRL-N) — Stockchase
Charles River Labs Intl (CRL-N) — Stockchase

Lost some gleam. Related to healthcare sector as a whole. Still confident in it. This is why you have a portfolio -- when some stocks fall, you have others to do the heavy lifting.

stockchase.com stockchase.com

Novartis AG (NVS-N)
One of the largest pharmaceutical companies based out of Switzerland. They are working on a drug called Kymriah that has the ability to reprogram a patient’s own immune cells.

Novartis AG (NVS-N) — Stockchase
Novartis AG (NVS-N) — Stockchase

Made big money by selling off one division. Decent pipelines. Looking to sell off generic division. Dividend grows, share buybacks. Healthcare has become front and centre, and that's not going away. Safe haven. Underpriced at these levels. Yield is 3.55%. (Analysts’ price target is $88.96)

stockchase.com stockchase.com

Regeneron Pharmaceuticals Inc (REGN-Q)
A biotechnology company that has multiple key drugs, including Eylea for macular degeneration. They have one of the largest human DNA sequencing project that will help with drug discovery and development.

Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase
Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase

Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.

stockchase.com stockchase.com

Sanofi-Aventis (SNY-N)
A french pharmaceutical company out of Paris that is the fifth largest in sales. They recently announced an over one billion dollar research deal with Denali Therapeutics for treatments for neurological and systemic inflammatory diseases.

Sanofi-Aventis (SNY-N) — Stockchase
Sanofi-Aventis (SNY-N) — Stockchase

(A Top Pick May 26/22, Down 12%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SNY has triggered its stop at $49. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 5.3%, when combined with previous buy recommendations.

stockchase.com stockchase.com

Thermo Fisher Scientific (TMO-N)
A biotechnology and pharmaceutical lab equipment company. They are paying down debt and have made some acquisitions that will grow well over the next couple of years.

Thermo Fisher Scientific (TMO-N) — Stockchase
Thermo Fisher Scientific (TMO-N) — Stockchase

Has owned company for 5 years. Is a good company to own within sector (way ahead of competition). Stock has fallen recently which is presenting good buying opportunity (25x P/E ratio). Dividend growing nicely with strong M&A activity. Buy shares now and if the price falls, buy more.

stockchase.com stockchase.com

United Therapeutics Corp. (UTHR-Q)
An American biotechnology company. Their primary drug therapy is for pulmonary disease. They acquired SteadyMed Therapeutics, a competitor with whom they were locked in a legal dispute with, last year.

United Therapeutics Corp. (UTHR-Q) — Stockchase
United Therapeutics Corp. (UTHR-Q) — Stockchase

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Allergan is a much larger company and more broadly-based, however, this one is a very fine company. Its primary drug therapy is dealing with pulmonary disease. The risk of owning this is that one drug represents a…

stockchase.com stockchase.com

Illumina Inc. (ILMN-Q)
One of the only companies that can do high volume DNA sequencing. They have brought down the cost of genetic sequencing to retail levels. They are becoming more available outside of research for commercial use in clinics.

Illumina Inc. (ILMN-Q) — Stockchase
Illumina Inc. (ILMN-Q) — Stockchase

(A Top Pick Jun 11/21, Down 58%) Company still growing in double digits. New M&A has yet to be recognized by market. Waiting to see whether there is valuation compression or whether fundamental problem with company. Will continue to hold shares in company.

stockchase.com stockchase.com

Gilead Sciences Inc. (GILD-Q)
An American biopharmaceutical company that is doing research on treating cancer using DNA targets to control it. They also released great results for a HIV treatment.

Gilead Sciences Inc. (GILD-Q) — Stockchase
Gilead Sciences Inc. (GILD-Q) — Stockchase

(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

stockchase.com stockchase.com

Bristol Myers Squibb (BMY-N)
They got hit due to problems with the Celegene acquisition. Some shareholders like it, others don’t. They have an innovative pipeline and their drugs using genetic technology has performed well, as well as the biotech that will come under their wing from Celegene.

Bristol Myers Squibb (BMY-N) — Stockchase
Bristol Myers Squibb (BMY-N) — Stockchase

(A Top Pick Dec 29/21, Up 21.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY is progressing well. To remain disciplined, we recommend trailing up the stop (from $68) to $72.

stockchase.com stockchase.com

Roche Holding (RHHBY-OTC)
A Swiss multinational healthcare company. They acquired a biotech firm that does research and development for all their future products. They have some promising drugs for multiple sclerosis and cancer treatment.

Roche Holding (RHHBY-OTC) — Stockchase
Roche Holding (RHHBY-OTC) — Stockchase

The Swiss drugmaker has received FDA emergency approval to allow medical professionals to use its antibody test to determine if people have ever been infected with the virus. The test looks for antibodies in someone's blood that are used to fight off the virus that causes. Those exposed to Covid-19, even if they showed no…

stockchase.com stockchase.com

CRISPR Therapeutics AG (CRSP-Q)
One of the smaller companies developing transformative gene medications. Their gene-editing tool is used to splice DNA that has the potential of curing diseases such as Huntington’s Chorea and cancer.

CRISPR Therapeutics AG (CRSP-Q) — Stockchase
CRISPR Therapeutics AG (CRSP-Q) — Stockchase

Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.

stockchase.com stockchase.com

0
Shares
  • Share On Facebook
  • Tweet It




Trending Now
3 gems from the Collision technology conference
Allan Tong June 29, 2022
Intertape Polymer Group and More at 52-week Highs & Lows (Jun 22-28)
Melisa R. H. June 29, 2022
Toys will always sell, 8 Toy Stocks to Buy in 2019
Read Next

Toys will always sell, 8 Toy Stocks to Buy in 2019

  • We're the Stock Chasers
    Hi! We are the Stock Chasers. We write about investing and finance tools we love. We’re passionate about fintech and we invest almost all our affiliate and advertising revenues into the development of Stockchase and Wealthica. We hope you enjoy the stock ideas and product reviews!
  • Top Reviews

    • Questrade Review: Pros & Cons of Trading with Questrade Canada (2021)
      8.5
    • Questrade vs Others | The Review Competitors Don’t Want you to Read (2021)
      7.4
    • The Ugly Truth About Identity Theft – Free Credit Report
      7
  • Popular Posts

    • 3 gems from the Collision technology conference
    • Intertape Polymer Group and More at 52-week Highs & Lows (Jun 22-28)
    • Reitmans, Medmira Inc More Earnings Reports this Week (Jun 27-Jul 01)
    • Air Canada, Shell plc and 19 Stock and 1 ETF Top Picks (Jun 17-23)
    • 3 defensive stocks to find stability with your money
  • Stock Lists

    • 3 defensive stocks to find stability with your money
      June 21, 2022
    • 3 rock stars of the mineral stocks
      June 15, 2022
    • 3 stocks to profit from revenge travel
      June 7, 2022
    • Are tech stocks alive?
      May 31, 2022
    • 3 dividend stocks to fight inflation
      May 24, 2022


  • Get $50 in free trades.


  • Stockchase neither recommends nor promotes any investment strategies.

    About us : Privacy & Terms : Contact us

© Stockchase Inc.
Press enter/return to begin your search